Diabetic neuropathies: Components of etiology

Journal of the Peripheral Nervous System

Volumn 13, Issue 2, 2008, Pages 112-121

  Tomlinson, David R ^a   Gardiner, Natalie J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Diabetes; MAP kinases; Nerve conduction; Neuropathy; Neurotrophins; Oxidative stress

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; GLUCOSE; ION CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE; SORBINIL;

APOPTOSIS; CAUSAL ATTRIBUTION; CONFERENCE PAPER; DIABETIC NEUROPATHY; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCATION; HUMAN; HYPERGLYCEMIA; METABOLIC DISORDER; NERVE CONDUCTION; NEUROPATHY; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCORING SYSTEM;

ANIMALS; DIABETIC NEUROPATHIES; GLUCOSE; HUMANS; INSULIN; MAP KINASE SIGNALING SYSTEM; OXIDATIVE STRESS;

EID: 45749127064     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00167.x     Document Type: Conference Paper

References (99)

1. Ahlgren SC, Levine JD (1993). Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 52 : 1049 1055.
2. Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G, Haik GM (2003). Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci 44 : 5287 5292.
3. Albers JW, Brown MB, Sima AAF, Greene DA (1996). Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Neurology 46 : 85 91.
4. Anand P, Terenghi G, Warner G, Kopelman PG, Williams-Chestnut RE, Sinicropi DV (1996). The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2 : 703 707.
5. Apfel SC (2002). Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 50 : 393 413.
6. Arezzo JC (1997). The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Commun 21 : 13 23.
7. Baba M, Ozaki I (2001). Electrophysiological changes in diabetic neuropathy: from subclinical alterations to disabling abnormalities. Arch Physiol Biochem 109 : 234 240.
8. Bagnasco SM, Balaban R, Fales HM, Yang YM, Burg MB (1986). Predominant osmotically active solutes in rat and rabbit renal medullas. J Biol Chem 261 : 5872 5877.
9. Bennett GS, Garrett NE, Diemel LT, Brain SD, Tomlinson DR (1998). Neurogenic cutaneous vasodilatation and plasma extravasation in diabetic rats: effect of insulin and nerve growth factor. Br J Pharmacol 124 : 1573 1579.
10. Bonny C, Borsello T, Zine A (2005). Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases. Rev Neurosci 16 : 57 67.
11. Boulton AJM, Armstrong W, Scarpello JHB, Ward JD (1983). The natural history of painful diabetic neuropathy - a 4 year study. Postgrad Med J 59 : 556 559.
12. Bril V (1999). NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 41 : 8 13.
13. Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H, Roche NSG (1998). Electrophysiological monitoring in clinical trials. Muscle Nerve 21 : 1368 1373.
14. Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414 : 813 820.
15. Burg MB (1988). Role of aldose reductase and sorbitol in maintaining the medullary intracellular milieu. Kidney Int 33 : 635 641.
16. Calcutt NA, Malmberg AB, Yamamoto T, Yaksh TL (1994). Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. Pain 58 : 413 420.
17. Calcutt NA, Li L, Yaksh TL, Malmberg AB (1995). Different effects of two aldose reductase inhibitors on nociception and prostaglandin E. Eur J Pharmacol 285 : 189 197.
18. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR (1996). Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68 : 293 299.
19. Cameron NE, Cotter MA, Maxfield EK (1993). Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin- diabetic rats. Diabetologia 36 : 299 304.
20. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK (1994). Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37 : 449 459.
21. Campbell JN, Meyer RA (2006). Mechanisms of neuropathic pain. Neuron 52 : 77 92.
22. Cheng C, Zochodne DW (2003). Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52 : 2363 2371.
23. Cheng HL, Feldman EL (1998). Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-I. J Biol Chem 273 : 14560 14565.
24. Cheng HL, Steinway M, Delaney CL, Franke TF, Feldman EL (2000). IGF-I promotes Schwann cell motility and survival via activation of Akt. Mol Cell Endocrinol 170 : 211 215.
25. ®) on diabetic neuropathy and neural function of the retina: a double-blind study. Acta Neurol Scand 71 : 164 167.
26. Courteix C, Eschalier A, Lavarenne J (1993). Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53 : 81 88.
27. Daulhac L, Mallet C, Courteix C, Etienne M, Duroux E, Privat AM, Eschalier A, Fialip J (2006). Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol 70 : 1246 1254.
28. Delaney CL, Cheng HL, Feldman EL (1999). Insulin-like growth factor-I prevents caspase-mediated apoptosis in Schwann cells. J Neurobiol 41 : 540 548.
29. Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977 986.
30. Dyck PJ (1988). Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 11 : 21 32.
31. Dyck PJ, O'Brien PC (1989). Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 12 : 649 652.
32. Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF (1988). Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 319 : 542 548.
33. Eliasson SG (1964). Nerve conduction changes in experimental diabetes. J Clin Invest 43 : 2353 2358.
34. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002). Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23 : 599 622.
35. Feki I, Lefaucheur JP (2001). Correlation between nerve conduction studies and clinical scores in diabetic neuropathy. Muscle Nerve 24 : 555 558.
36. Fernyhough P, Schmidt RE (2002). Neurofilaments in diabetic neuropathy. Int Rev Neurobiol 50 : 115 144.
37. Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, Tomlinson DR (1995). Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 7 : 1107 1110.
38. Fernyhough P, Diemel LT, Tomlinson DR (1998). Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozocin-diabetic rats. Diabetologia 41 : 300 306.
39. Fernyhough P, Gallagher A, Averill SA, Priestley JV, Hounsom L, Patel J, Tomlinson DR (1999). Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 48 : 881 889.
40. Gabbay KH, Merola LO, Field RA (1966). Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 151 : 209 210.
41. Gonen B, Bochenek WJ, Beg M, Graepel GJ (1991). The effect of withdrawal of tolrestat, an aldose reductase inhibitor, on signs, symptoms and nerve function in diabetic neuropathy. Diabetologia 34 : A153.
42. Greene DA, Winegrad AI (1979). In vitro studies of the substrates for energy production and the effects of insulin on glucose utilization in the neural components of peripheral nerve. Diabetes 28 : 878 887.
43. Greene DA, Brown MJ, Braunstein SN, Schwartz SS, Asbury AK, Winegrad AI (1981). Comparison of clinical course and sequential electrophysiological tests in diabetics with symptomatic polyneuropathy and its implications for clinical trials. Diabetes 30 : 139 147.
44. Greene DA, Stevens MJ, Obrosova I, Feldman EL (1999). Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 375 : 217 223.
45. Gregersen G (1968). Variations in motor conduction velocity produced by acute changes of the metabolic state in diabetic patients. Diabetologia 4 : 273 277.
46. Haslbeck KM, Neundorfer B, Schlotzer-Schrehardtt U, Bierhaus A, Schleicher E, Pauli E, Haslbeck M, Hecht M, Nawroth P, Heuss D (2007). Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies? Neurol Res 29 : 103 110.
47. Hellweg R, Hartung HD (1990). Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 26 : 258 267.
48. van Heyningen R (1959). Formation of polyols by the lens of the rat with 'sugar' cataracts. Nature 184 : 194 195.
49. Hounsom L, Horrobin DF, Tritschler H, Corder R, Tomlinson DR (1998). A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 41 : 839 843.
50. Hounsom L, Corder R, Patel J, Tomlinson DR (2001). Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia 44 : 424 428.
51. Huang TJ, Sayers NM, Fernyhough P, Verkhratsky A (2002). Diabetes-induced alterations in calcium homeostasis in sensory neurones of streptozotocin- diabetic rats are restricted to lumbar ganglia and are prevented by neurotrophin-3. Diabetologia 45 : 560 570.
52. Huang TJ, Sayers NM, Verkhratsky A, Fernyhough P (2005). Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats. Exp Neurol 194 : 279 283.
53. Jakus V, Rietbrock N (2004). Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 53 : 131 142.
54. Johnson GL, Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 : 1911 1912.
55. Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay KH, Rubenstein AH, Porte D Jr. (1983). Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 308 : 119 125.
56. Kultz D, Burg M (1998). Evolution of osmotic stress signaling via map kinase cascades. J Exp Biol 201 : 3015 3021.
57. Kultz D, Garcia-Perez A, Ferraris JD, Burg MB (1997). Distinct regulation of osmoprotective genes in yeast and mammals. Aldose reductase osmotic response element is induced independent of p38 and stress-activated protein kinase/Jun N-terminal kinase in rabbit kidney cells. J Biol Chem 272 : 13165 13170.
58. Lee JH, McCarty R (1992). Pain threshold in diabetic rats: effects of good versus poor diabetic control. Pain 50 : 231 236.
59. Llewelyn JG, Tomlinson DR, Thomas PK (2005). Diabetic neuropathies. In : Peripheral Neuropathy. Dyck PJ, Thomas PK (Eds). Elsevier Saunders, Philadelphia, pp 1951 1991.
60. Ludvigson MA, Sorenson RL (1980). Immunohistochemical localization of aldose reductase. I. Enzyme purification and antibody preparation - localization in peripheral nerve, artery and testis. Diabetes 29 : 438 449.
61. Malcangio M, Garrett NE, Bowery NG, Tomlinson DR (1996). Effect of 14-day treatment with nerve growth factor (NGF) on the release of substance P-like immunoreactivity from rat isolated spinal cord. Br J Pharmacol 118 : 48P.
62. Manning AM, Davis RJ (2003). Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2 : 554 565.
63. Medori R, Autilio-Gambetti L, Monaco S, Gambetti P (1985). Experimental diabetic neuropathy: impairment of slow transport with changes in axon cross-sectional area. Proc Natl Acad Sci U S A 82 : 7716 7720.
64. Medori R, Autilio-Gambetti L, Jenich H, Gambetti P (1988). Changes in axon size and slow axonal transport are related in experimental diabetic neuropathy. Neurology 38 : 597 601.
65. Mendell JR, Sahenk Z, Warmolts JR, Marshall JK, Thibert P (1981). The spontaneously diabetic BB Wistar rat. Morphologic and physiologic studies of peripheral nerve. J Neurol Sci 52 : 103 115.
66. Metz TO, Alderson NL, Thorpe SR, Baynes JW (2003). Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 419 : 41 49.
67. Mizisin AP, Calcutt NA, Tomlinson DR, Gallagher A, Fernyhough P (1999). Neurotrophin-3 reverses nerve conduction velocity deficits in streptozotocin-diabetic rats. J Peripher Nerv Syst 4 : 211 221.
68. Monnier VM (1996). Aminoguanidine and diabetic neuropathy. Eur J Endocrinol 134 : 398 400.
69. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 : 787 790.
70. Nishimura C, Lou MF, Kinoshita JH (1987). Depletion of myo-inositol and amino acids in galactosemic neuropathy. J Neurochem 49 : 290 295.
71. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ (2002). An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16 : 123 125.
72. Obrosova IG, Drel VR, Pacher P, Ilnytska O, Wang ZQ, Stevens MJ, Yorek MA (2005a). Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54 : 3435 3441.
73. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, Szabo C (2005b). Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19 : 401 403.
74. O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IAD, Corrall RJM (1988). Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabet Med 5 : 537 542.
75. Piao ZG, Cho IH, Park CK, Hong JP, Choi SY, Lee SJ, Lee S, Park K, Kim JS, Oh SB (2006). Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 121 : 219 231.
76. Price SA, Agthong S, Middlemas AB, Tomlinson DR (2004). Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 53 : 1851 1856.
77. Price SA, Zeef LAH, Wardleworth L, Hayes A, Tomlinson DR (2006). Identification of changes in gene expression in dorsal root ganglia in diabetic neuropathy: correlation with functional deficits. J Neuropathol Exp Neurol 65 : 722 732.
78. Purves TD, Middlemas A, Agthong S, Jude EB, Boulton AJM, Fernyhough P, Tomlinson DR (2001). A role for mitogen-activated protein kinases in the aetiology of diabetic neuropathy. FASEB J 15 : 2508 2514.
79. Rafiuddin AM, Jayakumar R (2003). Peripheral nerve regeneration in RGD peptide incorporated collagen tubes. Brain Res 993 : 208 216.
80. Ramos KM, Jiang Y, Svensson CI, Calcutt NA (2007). Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 56 : 1569 1576.
81. Raz I, Hasdai D, Seltzer Z, Melmed RN (1988). Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. Diabetes 37 : 1253 1259.
82. Roy TM, Broadstone VL, Peterson HR, Snider HL, Cyrus J, Fell R, Rothchild AH, Samols E, Pfeifer MA (1990). The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. Diabetes Res Clin Pract 10 : 91 97.
83. Sayers NM, Beswick LJ, Middlemas A, Calcutt NA, Mizisin AP, Tomlinson DR, Fernyhough P (2003). Neurotrophin-3 prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats. Diabetes 52 : 2372 2380.
84. Singh R, Barden A, Mori T, Beilin L (2001). Advanced glycation end-products: a review. Diabetologia 44 : 129 146.
85. Sundkvist G, Lilja B, Rosén I, Agardh CD (1987). Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function. Acta Med Scand 221 : 445 453.
86. Thornalley PJ, Bellavite P (1987). Modification of the glyoxalase system during the functional activation of human neutrophils. Biochim Biophys Acta 931 : 120 129.
87. Thye-Ronn P, Sindrup SH, Arendt-Nielsen L, Brennum J, Hother-Nielsen O, Beck-Nielsen H (1994). Effect of short-term hyperglycemia per se on nociceptive and non-nociceptive thresholds. Pain 56 : 43 49.
88. Tomlinson DR, Holmes PR, Mayer JH (1982). Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus. Neurosci Lett 31 : 189 193.
89. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K (2004). Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 45 : 89 95.
90. Vincent AM, McLean LL, Backus C, Feldman EL (2005). Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 19 : 638 640.
91. Walsh GS, Orike N, Kaplan DR, Miller FD (2004). The invulnerability of adult neurons: a critical role for p73. J Neurosci 24 : 9638 9647.
92. Whitworth IH, Terenghi G, Green CJ, Brown RA, Stevens E, Tomlinson DR (1995). Targeted delivery of nerve growth factor via fibronectin conduits assists nerve regeneration in control and diabetic rats. Eur J Neurosci 7 : 2220 2225.
93. Willars GB, Townsend J, Tomlinson DR, Compton AM, Churchill RD (1988). Studies on peripheral nerve and lens in long-term experimental diabetes: effects of the aldose reductase inhibitor statil. Metabolism 37 : 442 449.
94. Wittmack EK, Rush AM, Hudmon A, Waxman SG, Dib-Hajj SD (2005). Voltage-gated sodium channel Nav1.6 is modulated by p38 mitogen-activated protein kinase. J Neurosci 25 : 6621 6630.
95. Wuarin-Bierman L, Zahnd GR, Kaufmann F, Burcklen L, Adler J (1987). Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia 30 : 653 658.
96. Xu JT, Xin WJ, Wei XH, Wu CY, Ge YX, Liu YL, Zang Y, Zhang T, Li YY, Liu XG (2007). p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp Neurol 204 : 355 365.
97. Yang SH, Sharrocks AD, Whitmarsh AJ (2003). Transcriptional regulation by the MAP kinase signaling cascades. Gene 320 : 3 21.
98. Young RJ, Ewing DJ, Clarke BF (1983). A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 32 : 938 942.
99. Ziegler D, Reljanovic M, Mehnert H, Gries FA (1999). a-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 107 : 421 430.